blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3052943

EP3052943 - BIOMARKERS FOR CELL THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.09.2020
Database last updated on 13.07.2024
FormerThe patent has been granted
Status updated on  18.10.2019
FormerGrant of patent is intended
Status updated on  16.05.2019
FormerExamination is in progress
Status updated on  07.12.2018
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Cell Ideas Pty Ltd.
25 Bridge Street
Pymble, NSW 2073 / AU
[2016/32]
Inventor(s)01 / HERBERT, Ben
3 Douglas Avenue
North Epping, NSW 2121 / AU
 [2016/32]
Representative(s)Huenges, Martin
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
[N/P]
Former [2019/47]Huenges, Martin
Maiwald Patentanwalts- und
Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
Former [2016/32]Huenges, Martin
Maiwald Patentanwalts GmbH
Elisenhof
Elisenstrasse 3
80335 München / DE
Application number, filing date14851360.903.10.2014
[2016/32]
WO2014AU00951
Priority number, dateAU2013090384004.10.2013         Original published format: AU 2013903840
[2016/32]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015048842
Date:09.04.2015
Language:EN
[2015/14]
Type: A1 Application with search report 
No.:EP3052943
Date:10.08.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 09.04.2015 takes the place of the publication of the European patent application.
[2016/32]
Type: B1 Patent specification 
No.:EP3052943
Date:20.11.2019
Language:EN
[2019/47]
Search report(s)International search report - published on:AU09.04.2015
(Supplementary) European search report - dispatched on:EP03.08.2017
ClassificationIPC:G01N33/68, A61K35/12, A61P1/00, A61P19/02, A61P37/00
[2016/32]
CPC:
G01N33/6893 (EP,KR,US); A61K35/28 (EP,KR,US); A61K35/35 (EP,KR,US);
A61P1/00 (EP); A61P19/02 (EP); A61P19/08 (EP);
A61P29/00 (EP); A61P37/00 (EP); G01N2800/102 (EP,KR,US);
G01N2800/105 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/32]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:BIOMARKER FÜR EINE ZELLTHERAPIE[2016/32]
English:BIOMARKERS FOR CELL THERAPY[2016/32]
French:BIOMARQUEURS POUR THÉRAPIE CELLULAIRE[2016/32]
Entry into regional phase27.04.2016National basic fee paid 
27.04.2016Search fee paid 
27.04.2016Designation fee(s) paid 
27.04.2016Examination fee paid 
Examination procedure04.08.2015Request for preliminary examination filed
International Preliminary Examining Authority: AU
27.04.2016Examination requested  [2016/32]
01.03.2018Amendment by applicant (claims and/or description)
11.12.2018Despatch of a communication from the examining division (Time limit: M04)
02.04.2019Reply to a communication from the examining division
17.05.2019Communication of intention to grant the patent
25.09.2019Fee for grant paid
25.09.2019Fee for publishing/printing paid
25.09.2019Receipt of the translation of the claim(s)
Opposition(s)21.08.2020No opposition filed within time limit [2020/44]
Fees paidRenewal fee
11.10.2016Renewal fee patent year 03
11.10.2017Renewal fee patent year 04
11.10.2018Renewal fee patent year 05
15.10.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.10.2014
AL20.11.2019
AT20.11.2019
CY20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
IT20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
MK20.11.2019
MT20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
TR20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
[2022/32]
Former [2022/27]HU03.10.2014
AL20.11.2019
AT20.11.2019
CY20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
IT20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
MT20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
TR20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2021/31]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
IT20.11.2019
LT20.11.2019
LV20.11.2019
MC20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2021/10]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
IT20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/51]AL20.11.2019
AT20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
PL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SI20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/37]AL20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
SK20.11.2019
SM20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/36]AL20.11.2019
CZ20.11.2019
DK20.11.2019
EE20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
PT12.04.2020
Former [2020/35]AL20.11.2019
CZ20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RO20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/34]AL20.11.2019
ES20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/32]AL20.11.2019
FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/26]FI20.11.2019
HR20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
RS20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/24]FI20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
IS20.03.2020
Former [2020/23]FI20.11.2019
LT20.11.2019
LV20.11.2019
NL20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
GR21.02.2020
Former [2020/22]FI20.11.2019
LT20.11.2019
SE20.11.2019
BG20.02.2020
NO20.02.2020
Former [2020/21]NO20.02.2020
Documents cited:Search[Y]WO9851317  (OSIRIS THERAPEUTICS INC [US], et al) [Y] 1-17 *cf. abstract, page 4, 2nd para. bridging with 5, 2nd para., claims*;
 [Y]US2011212104  (BEAUMONT MARIBEL [US], et al) [Y] 1-17 *cf. abstract, section [0019] at page 2, claims 1, 23-25*;
 [Y]US2011293577  (VESEY GRAHAM [AU]) [Y] 1-17 *cf. abstract, sections [0005] to [0015] at page 1*;
 [Y]WO2013023233  (ALFRED HEALTH [AU], et al) [Y] 1-17 *cf. abstract, claim 1*;
 [Y]EP2639296  (OTSUKA PHARMA CO LTD [JP], et al) [Y] 1-17 *cf. abstract, sections [0004] and [0005] at page 2 *;
 [YP]US2014248638  (THIELE MICHAEL [AT], et al) [YP] 1-17 *cf. abstract, claims 1 and 7*;
 [Y]  - YPE P. DE JONG ET AL, "Development of chronic colitis is dependent on the cytokine MIF", NATURE IMMUNOLOGY, (20011101), vol. 2, no. 11, doi:10.1038/ni720, ISSN 1529-2908, pages 1061 - 1066, XP055332397 [Y] 1-17 *cf. summary and discussion part at page 1064, last para. of the right col. bridging with left-sided col. at page 1065*

DOI:   http://dx.doi.org/10.1038/ni720
 [Y]  - JONES E1 ET AL, "Mesenchymal stem cells in rheumatoid synovium: enumeration and functional assessment in relation to synovial inflammation level", ANNALS OF THE RHEUMATIC DISEASES, BRITISH MEDICAL ASSOCIATION, GB, (20100201), vol. 69, no. 2, doi:10.1136/ARD.2008.106435, ISSN 0003-4967, pages 450 - 457, XP009193981 [Y] 1-17 *cf. abstract, page 452, 2nd para. of the left col., bridging with 1st para. of the right-hand col.*

DOI:   http://dx.doi.org/10.1136/ard.2008.106435
International search[A]WO03024215  (MACROPORE BIOSURGERY INC [US]);
 [X]WO2010062663  (SCHERING CORP [US], et al);
 [X]WO2013050453  (BAXTER HEALTHCARE SA [CH], et al);
 [A]  - MOBASHERI, A. ET AL., "Biomarkers of Osteoarthritis: A Review of Recent Research Progress on Soluble Biochemical Markers, Published Patents and Areas for Future Development", RECENT PATENTS OF BIOMARKERS, (2011), vol. 1, pages 25 - 43, XP055332388

DOI:   http://dx.doi.org/10.2174/2210310411101010025
 [X]  - HOES, J.N. ET AL., "Changes in macrophage inhibitory factor correlate with changes in bone mineral density in glucocorticoid-treated patients with rheumatoid arthritis", RHEUMATOLOGY, (2011), vol. 50, pages 1921 - 1924, XP055332391

DOI:   http://dx.doi.org/10.1093/rheumatology/ker268
 [X]  - KASAMA, T. ET AL., "Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis", RHEUMATOLOGY INTERNATIONAL, (20130514), vol. 34, no. 3, pages 429 - 433, XP055332394

DOI:   http://dx.doi.org/10.1007/s00296-013-2778-0
 [X]  - DE JONG, Y.P. ET AL., "Development of chronic colitis is dependent on the cytokine MIF", NATURE IMMUNOLOGY, (2001), vol. 2, no. 11, pages 1061 - 1066, XP055332397

DOI:   http://dx.doi.org/10.1038/ni720
 [X]  - REN, Y. ET AL., "Up-regulation of macrophage migration inhibitory factor in infants with acute neonatal necrotizing enterocolitis", HISTOPATHOLOGY, (2005), vol. 46, no. 6, pages 659 - 667, XP055332400

DOI:   http://dx.doi.org/10.1111/j.1365-2559.2005.02159.x
 [A]  - PAK, J., "Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series", JOURNAL OF MEDICAL CASE REPORTS, (2011), vol. 5, no. 296, pages 1 - 8, XP021106048

DOI:   http://dx.doi.org/10.1186/1752-1947-5-296
 [A]  - LANZONI, G. ET AL., "Inflammatory bowel disease: Moving toward a stem cell -based therapy", WORLD JOURNAL OF GASTROENTEROLOGY, (2008), vol. 14, no. 29, pages 4616 - 4626, XP055127973

DOI:   http://dx.doi.org/10.3748/wjg.14.4616
by applicantWO9851317
 AU2009201915B
 WO2010020005
 US2011029357
 US2011212104
 WO2012122603
 WO2013023233
 WO2013040649
 EP2639296
 AU2013204930B
 US2014248638
    - JONG Y. P. et al., Nature Immunology, (20010000), vol. 2, no. 11
    - Methods in Cell Biology: Antibodies in Cell Biology, (19930000), vol. 37
    - ALEXANDER et al., Exp Neurol., (20120800), vol. 236, no. 2, pages 351 - 362
    - V.B. KRAUS et al., Osteoarthritis and Cartilage, (20110000), vol. 19
    - BLABER SP; WEBSTER RA; HILL CJ et al., "Analysis of in vitro secretion profiles from adipose-derived cell populations", J Transl Med, (20120000), vol. 10, pages 172 - 88
    - J Orthop Res., (20130700), vol. 31, no. 7, pages 999 - 1006
 WO2009AU01070
 WO2012AU00272
 WO2012AU01140
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.